ArticleThe World Allergy Organization journal2025
Enhanced allergic Eustachian tube response in surfactant protein D knockout mice induced by ovalbumin.
Article in The World Allergy Organization journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Correlation study on different types of chronic sinusitis and eustachian tube dysfunction: analysis of prevalence and risk factors.Clinics (Sao Paulo, Brazil) · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Allergic reactions have been widely recognized as closely associated with the development of Eustachian tube dysfunction (ETD). However, the precise pathophysiological mechanisms remain unclear, and effective models to elucidate the role of allergic responses in ETD are lacking. Surfactant protein D (SPD), an important immune defense factor in the Eustachian tube (ET), not only reduces surface tension but also exhibits anti-adhesion and inflammation-regulating properties. Nevertheless, the role of SPD in allergic inflammation of the ET has not been fully explored. Objective: This study aimed to investigate the morphological and functional changes in the ET induced by ovalbumin under SPD gene deficiency and to explore the underlying mechanisms. Methods: Experimental models were established using C57 mice with different SPD genotypes, divided into control groups (WT-PBS and SPD-KO-PBS) and allergic groups (WT-OVA and SPD-KO-OVA). Allergic symptoms were recorded following intraperitoneal OVA injection and nasal challenges, and serum total IgE levels were measured. Histological methods were used to evaluate the number and morphological changes of eosinophils in the ET. Immunostaining was performed to analyze the secretion of Muc5b and Muc5ac. ET function was assessed by measuring passive opening pressure (POP) and comparing active clearance of negative pressure (ACNP). Mucociliary clearance (MCC) was evaluated using small-animal imaging techniques. Exogenous SPD was administered intranasally to SPD-KO-OVA mice to evaluate therapeutic effects. Results: Allergic mice exhibited significant inflammatory features, including increased sneezing frequency, elevated serum IgE levels, eosinophil infiltration in the ET mucosa, goblet cell hyperplasia, and abnormal mucin secretion. Meanwhile, ACNP and MCC functions were significantly impaired. Compared with the WT-OVA group, SPD-KO-OVA mice demonstrated more severe eosinophil infiltration, thickened ET mucosa, enhanced mucus gland secretion, elevated POP, and further impaired ACNP and MCC functions, with excessive mucus accumulation in the middle ear cavity. Abnormal overexpression of Muc5ac and Muc5b may further exacerbate OVA-induced ET dysfunction. Intranasal SPD treatment significantly attenuated mucosal inflammation, reduced eosinophil infiltration and mucin production, and restored ACNP function in SPD-KO-OVA mice. Conclusions: SPD plays a critical role in regulating allergic inflammation and protecting ET function. Its deficiency exacerbates OVA-induced inflammation and functional impairment of the ET, while exogenous SPD administration ameliorates tissue inflammation and restores ACNP efficacy. These findings highlight SPD as a therapeutic target for allergic ETD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.